Downregulation of ROS1 enhances the therapeutic efficacy of arsenic trioxide in acute myeloid leukemia cell lines

Li,Jun

doi:10.3892/ol.2018.8458

Downregulation of ROS1 enhances the therapeutic efficacy of arsenic trioxide in acute myeloid leukemia cell lines

Authors:
- Jun Li
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Published online on: April 10, 2018 https://doi.org/10.3892/ol.2018.8458
Pages: 9392-9396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the function of ROS proto‑oncogene 1 receptor tyrosine kinase (ROS1) in regulating the migration and proliferation of acute myeloid leukemia (AML) cells through Wnt/β‑catenin signaling, and in arsenic trioxide (ATO) treatment. The migration and proliferation of multiple ROS1‑silenced leukemic cell lines was assessed, and the expression levels of proteins associated with Wnt/β‑catenin signaling were determined using western blot analysis. Compared with the AML control cells, ROS1‑knockdown cells exhibited increased migration and proliferation, and the significant downregulation of β‑catenin expression. Additionally, ROS1 knockdown sensitized AML cells to the effects of chemotherapeutic ATO. The results of the present study demonstrated that, in leukemic cell lines, ROS1 counteracted the effects of ATO on migration and proliferation, suggesting that ROS1 may be a potential therapeutic target in patients with AML undergoing ATO treatment. The results of the present study provided novel insight into the function of ATO and ROS1 in regulating AML progression.

View Figures

View References

1	Estey E and Döhner H: Acute myeloid leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
2	Estey EH: Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 88:318–327. 2013. View Article : Google Scholar : PubMed/NCBI
3	Coombs CC, Tavakkoli M and Tallman MS: Acute promyelocytic leukemia: Where did we start, where are we now, and the future. Blood Cancer J. 5:e3042015. View Article : Google Scholar : PubMed/NCBI
4	Cicconi L and Lo-Coco F: Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol. 27:1474–1481. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lo-Coco F, Cicconi L and Breccia M: Current standard treatment of adult acute promyelocytic leukaemia. Br J Haematol. 172:841–854. 2016. View Article : Google Scholar : PubMed/NCBI
6	Sanz MA and Lo-Coco F: Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 29:495–503. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhu J, Chen Z, Lallemand-Breitenbach V and de Thé H: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2:705–713. 2002. View Article : Google Scholar : PubMed/NCBI
8	de Thé H and Chen Z: Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer. 10:775–783. 2010. View Article : Google Scholar : PubMed/NCBI
9	Takahashi S: Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem. 10:504–510. 2010. View Article : Google Scholar : PubMed/NCBI
10	Shaw AT, Hsu PP, Awad MM and Engelman JA: Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 13:772–787. 2013. View Article : Google Scholar : PubMed/NCBI
11	El-Deeb IM, Yoo KH and Lee SH: ROS receptor tyrosine kinase: A new potential target for anticancer drugs. Med Res Rev. 31:794–818. 2011.PubMed/NCBI
12	Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, Wu J, Ren X and Zhang J: ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget. 7:12289–12304. 2016. View Article : Google Scholar : PubMed/NCBI
13	Arnaoutakis K: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 372:6832015. View Article : Google Scholar : PubMed/NCBI
14	Gold KA: ROS1-targeting the one percent in lung cancer. N Engl J Med. 371:2030–2031. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lambros L, Guibourg B and Uguen A: ROS1-rearranged non-small cell lung cancers with concomitant oncogenic driver alterations: About some rare therapeutic dilemmas. Clin Lung Cancer. 19:e73–e74. 2018. View Article : Google Scholar : PubMed/NCBI
16	Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the national cancer institute cooperative research and development studies. Oncologist. 6 Suppl 2:S22–S28. 2001. View Article : Google Scholar
17	Tallman MS: What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol. 21:659–666. 2008. View Article : Google Scholar : PubMed/NCBI
18	Berenson JR and Yeh HS: Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy. Clin Lymphoma Myeloma. 7:192–198. 2006. View Article : Google Scholar : PubMed/NCBI
19	Evens AM, Tallman MS and Gartenhaus RB: The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future. Leuk Res. 28:891–900. 2004. View Article : Google Scholar : PubMed/NCBI
20	Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F and Ferrero E: Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat. 73:61–73. 2002. View Article : Google Scholar : PubMed/NCBI
21	Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY and Chen SJ: Expanding the use of arsenic trioxide: Leukemias and beyond. Semin Hematol. 39 2 Suppl 1:S22–S26. 2002. View Article : Google Scholar
22	Dilda PJ and Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev. 33:542–564. 2007. View Article : Google Scholar : PubMed/NCBI
23	Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E and Kantarjian H: Arsenic derivatives in hematologic malignancies: A role beyond acute promyelocytic leukemia? Hematol Oncol. 24:181–188. 2006. View Article : Google Scholar : PubMed/NCBI
24	Eaves CJ and Humphries RK: Acute myeloid leukemia and the Wnt pathway. N Engl J Med. 362:2326–2327. 2010. View Article : Google Scholar : PubMed/NCBI
25	Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, Lainey E, Nouri K, Nakhaei-Rad S, Dvorsky R, et al: Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 47:1334–1340. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, et al: The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 44:861–871. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, et al: Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood. 125:2985–2994. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI and Armstrong SA: The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 327:1650–1653. 2010. View Article : Google Scholar : PubMed/NCBI
29	Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW and Armstrong SA: Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 10:412–424. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kleppe M and Levine RL: Targeting β-catenin in CML: Leukemia stem cells beware! Cell Stem Cell. 10:351–353. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemler R: Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
32	Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS and Ogino S: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 305:1685–1694. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wang K, Li N, Yeung CH, Cooper TG, Liu XX, Liu J, Wang WT, Li Y, Shi H and Liu FJ: Comparison of gene expression of the oncogenic Wnt/β-catenin signaling pathway components in the mouse and human epididymis. Asian J Androl. 17:1006–1011. 2015. View Article : Google Scholar : PubMed/NCBI